OncoMatch/Clinical Trials/NCT04401059
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study
Is NCT04401059 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Elemene plus first or third generation EGFR-TKIs and First or third generation EGFR-TKIs for carcinoma.
Treatment: Elemene plus first or third generation EGFR-TKIs · First or third generation EGFR-TKIs — This is a nationwide, multicenter and prospective cohort study. The purpose of this study is to evaluate the synergistic effect and safety of Elemene plus TKIs in EGFR-mutated advanced non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR ex19del
EGFR mutations (deletions in exon 19 and L858R in exon 21 of the EGFR gene)
Required: EGFR L858R
EGFR mutations (deletions in exon 19 and L858R in exon 21 of the EGFR gene)
Disease stage
Required: Stage IIIB, IV
Prior therapy
Cannot have received: EGFR tyrosine kinase inhibitor combined with chemotherapy or anti-angiogenesis therapy
Exposure to First- or third-generation EGFR-TKIs combined treatment, for example, chemotherapy, anti-angiogenesis therapy
Cannot have received: elemene
Exception: no prior exposure within one month
No prior exposure to elemene injectable and/or oral emulsion within one month
Cannot have received: Chinese patent medicine with similar efficacy
Exception: if more than one month, 30-day washout period required
Prior exposure to other Chinese patent medicine with similar efficacy within one month. If more than one month, patients can be enrolled after a 30-day washout period (without continuing to use the above medications)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify